Plus Therapeutics
Open
$6.09
Prev. Close
$6.09
High
$6.11
Low
$6.09
Market Snapshot
$30.78M
-1.4
-2.06
$5.82M
28
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
emptyResult
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas. The company went IPO on 2000-08-09. The firm is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Recently from Cashu
Plus Therapeutics Navigates Industry Scrutiny Amid Legal Challenges in Pharma Sector
Plus Therapeutics Faces Industry Challenges Amid Legal Developments in Pharma Sector In the evolving landscape of the pharmaceutical industry, Plus Therapeutics remains vigilant amidst a backdrop of h…
Plus Therapeutics: Urgent Call for Transparency Amid Pharmaceutical Sector Crisis
Crisis of Transparency in the Pharmaceutical Sector: A Wake-Up Call for Companies Like Plus Therapeutics In the wake of a recent class action lawsuit filed against Cytokinetics, an urgent spotlight sh…
Plus Therapeutics: Navigating Transparency and Trust in Pharmaceutical Development Challenges
Transparency in Pharmaceutical Development: A Call for Industry Vigilance In the complex landscape of the pharmaceutical industry, transparency remains a critical pillar for maintaining investor trust…
Plus Therapeutics: Promising Advances in Cancer Treatment with GTB-3650 Immunotherapy Trial
Innovative Advances in Cancer Treatment: GT Biopharma's Promising Trial GT Biopharma, Inc., a clinical-stage immunotherapy company based in San Francisco, is at the forefront of innovative cancer trea…